GAB1

Last update 08 May 2025

Basic Info

Synonyms

DFNB26, GAB1, GRB2 associated binding protein 1

+ [3]

Introduction

Adapter protein that plays a role in intracellular signaling cascades triggered by activated receptor-type kinases. Plays a role in FGFR1 signaling. Probably involved in signaling by the epidermal growth factor receptor (EGFR) and the insulin receptor (INSR). Involved in the MET/HGF-signaling pathway (PubMed:29408807).

100 Clinical Results associated with GAB1

100 Translational Medicine associated with GAB1

0 Patents (Medical) associated with GAB1

650

Literatures (Medical) associated with GAB1

01 Jun 2025·Annals of Diagnostic Pathology

Molecular classification of medulloblastoma using immunohistochemistry: A single centre study

Article

Author: Mwazha, Absalom ; Shezi, Nomusa B ; Harry, Jason L

Medulloblastoma (MB) is the second most common malignant paediatric central nervous system (CNS) tumour. The World Health Organisation (WHO) advocates an integrated pathological and molecular approach to diagnosis. Immunohistochemistry (IHC) has been proven to be a valid surrogate for molecular subtyping in low resource settings. This study aimed to use IHC to classify MB into different molecular subtypes. Patients diagnosed with medulloblastoma between 2011 and 2021 were included in the study. Clinicopathological characteristics, treatment patterns and outcomes were reviewed. Molecular subgrouping into wingless signalling activated (WNT), sonic hedgehog (SHH), and non-WNT/non-SHH was performed by immunohistochemical staining, using β-catenin, Yes-associated protein 1 (YAP1) and GRB2-Associated Binding Protein 1 (GAB1) antibodies. Of the 32 children evaluated, the mean age at diagnosis was 9.9 years with M: F ratio of 1.5:1. Classic (75.8 %) and desmoplastic/nodular (24.2 %) were the only two histopathological variants reported. Non-WNT/non-SHH constituted the majority of cases (54.5 %), followed by SHH (36.4 %) and WNT subgroups (9.1 %). The 5-year overall survival and 5-year progression-free survival was 41 % and 38 % respectively. The 30-day operative mortality rate was 28.1 %. Molecular subgroups determined by immunohistochemistry, can be easily incorporated into routine practice in low resource settings. The overall survival rate in our cohort is lower than thate reported in the literature due to high post-operative mortality and low uptake of adjuvant oncotherapy.

01 Mar 2025·Journal of Clinical Pathology

Emerging fusion-associated mesenchymal tumours: a tabular guide and appraisal of five ‘novel’ entities

Review

Author: Moodley, Jinesa ; Chebib, Ivan

AimsThe field of molecular pathology has undergone significant advancements in the clinical impact of sarcoma diagnosis, resulting in challenges to nosology of bone and soft tissue tumours. The surge in molecular data has led to the identification of novel fusions and description of new ‘entities’. To illustrate this, we have selected five emerging entities with novel fusions: clear cell stromal tumour of the lung withYAP1::TFE3fusion,GAB1::ABL1fusion spindle cell neoplasm,NUTM1-rearranged sarcomas,NR1D1-rearranged sarcomas and calcified chondroid mesenchymal neoplasms.MethodsLiterature for the relevant case reports and case series of these five entities were reviewed and clinicopathological data was collected. Additionally, this review includes a table format of recently described fusion-associated mesenchymal neoplasms.ResultsThe morphological and immunohistochemical features, along with diagnostic challenges, are discussed for each entity.ConclusionsHere, we have provided a review of selected emerging mesenchymal neoplasms, which of these neoplasms will meet the threshold to be ‘new entities’ remains to be determined.

01 Feb 2025·Cardiovascular Drugs and Therapy

Gab1 in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area

Letter

Author: Ren, Li-Ying ; Jing, Da-Tan ; Li, Fei

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

GAB1

Basic Info

Related

Analysis